Entity
PRDM1-PGC1A Axis in CAR T Cell Exhaustion
New preclinical research identifies the PRDM1 (BLIMP-1)-PGC1A axis as a driver of CAR T cell exhaustion and a potential therapeutic target to improve efficacy against B cell malignancies. This is relevant to the fast-moving cell therapy biotech and IP landscape.
This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →
## Overview
Researchers have identified the transcription factor PRDM1 (encoding BLIMP-1) as a key regulator of CAR T cell terminal differentiation and exhaustion, with therapeutic implications for improving CAR T cell efficacy against B cell malignancies (bioRxiv, Oct 21).
## Key Findings
- PRDM1 was found to be highly enriched in exhausted-like tumor-infiltrating CAR T cells from lymphoma patients and in pre-infusion CAR T products from clinical non-responders (bioRxiv, Oct 21).
- The study links increased PRDM1 expression to CAR T cell dysfunction, implicating the PRDM1-PGC1A axis as a mechanism underlying resistance to CAR T therapy (bioRxiv, Oct 21).
- The work suggests that targeting this axis could enhance CAR T cell stemness, persistence, and effector function — addressing a major limitation of current CAR T therapies for B cell malignancies (bioRxiv, Oct 21).
## Why It Matters
CAR T cell therapy has transformed treatment for certain blood cancers but remains limited by durability and resistance issues. Identifying druggable regulators of CAR T exhaustion, like PRDM1, has direct relevance to next-generation cell therapy development, biotech IP strategy, and licensing — a space of significant commercial and patent activity.
## Outlook
This finding is likely to be followed by efforts to therapeutically modulate PRDM1 or PGC1A (e.g., via genetic engineering or small molecules) in CAR T products, a space of active biotech investment and clinical development.